What Apimeds Pharmaceuticals US Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Emerson Erik | Chief Executive Officer | May 16 | Grant / award · A | +750,000 | — | — | 750,000 |
| Kim Christopher | Chairman and CMO | May 16 | Grant / award · A | +250,000 | — | — | 277,500 |
| Kim Christopher | Chairman and CMO | May 14 | Open-market buy · P | +7,730 | $1.86 | +$14.4K | 27,500 |
| Kim Christopher | Chairman and CMO | May 13 | Open-market buy · P | +19,770 | $1.82 | +$36K | 19,770 |
| Inscobee Inc. | 10% owner | May 12 | Derivative Conversion · C | +44,041 | $2.60 | +$115K | 2,099,747 |
| Inscobee Inc. | 10% owner | May 12 | Derivative Conversion · C | +71,090 | $2.60 | +$185K | 2,055,706 |
| Koo Jakap | Director | May 12 | Open-market buy · P | +28,500 | $1.99 | +$56.7K | 643,885 |
Loading...
